What is Allozymes?
Allozymes operates at the intersection of synthetic biology and industrial efficiency. The company specializes in the rapid discovery and engineering of enzymes, utilizing a proprietary microfluidics-based platform that significantly accelerates the development cycle for sustainable biosolutions. By serving diverse sectors—including pharmaceuticals, food and nutrition, and bioremediation—Allozymes provides a critical infrastructure for companies aiming to decarbonize their supply chains and improve product performance.
Their business model is built on a dual-track approach: offering bespoke enzyme engineering services and licensing high-performance biosolutions. This strategy positions the firm as a key enabler for global enterprises seeking to replace chemical-heavy processes with cleaner, more efficient biological alternatives, thereby aligning with global sustainability mandates.
How much funding has Allozymes raised?
Allozymes has raised a total of $20M across 2 funding rounds:
Angel/Seed
$5M
Series A
$15M
Angel/Seed (2021): $5M with participation from Entrepreneur First, Xora Innovation, TI Platform Management, and HAX
Series A (2024): $15M led by SOSV, Seventure Partners, and Entrepreneur First
Key Investors in Allozymes
SOSV
SOSV is a multi-stage venture capital investor that provides intellectual and financial capital to accelerate founders big ideas.
Seventure Partners
Seventure Partners is an active partner of innovative companies in the fields of digital technologies and life sciences, focusing on environmental challenges through biotechnologies.
Entrepreneur First
Entrepreneur First is an international Talent Investor, which supports individuals to build technology companies from the ground up.
What's next for Allozymes?
With the successful closure of this major enterprise-level funding, Allozymes is well-positioned to scale its operational capacity and expand its commercial footprint. The strategic roadmap likely involves deepening its R&D capabilities to address more complex molecular challenges while simultaneously broadening its partnership network across the life sciences and chemical industries.
As the company moves into this growth phase, the focus will shift toward optimizing its microfluidics throughput and securing long-term licensing agreements with multinational corporations. By maintaining its commitment to innovation, Allozymes is set to solidify its role as a foundational player in the global transition toward a bio-based economy, leveraging its recent capital to bridge the gap between laboratory-scale discovery and industrial-scale application.
